Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Identification of drug-specific public TCR driving severe cutaneous adverse reactions.

Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, Schutte R, Ostrov DA, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T, Tassaneeyakul W, White KD, Roujeau JC, Chung WH, Hung SI.

Nat Commun. 2019 Aug 8;10(1):3569. doi: 10.1038/s41467-019-11396-2.

2.

Making a diagnosis in severe cutaneous drug hypersensitivity reactions.

Ardern-Jones MR, Mockenhaupt M.

Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):283-293. doi: 10.1097/ACI.0000000000000546.

PMID:
31247634
3.

Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.

Reschke R, Mockenhaupt M, Simon JC, Ziemer M.

J Dtsch Dermatol Ges. 2019 Jun 18. doi: 10.1111/ddg.13876. [Epub ahead of print] No abstract available.

PMID:
31210413
4.

[25-year-old female with rapidly progressing exanthema with blistering and mucosal involvement : Preparation for the specialist examination: part 54].

Mockenhaupt M.

Hautarzt. 2019 Apr;70(Suppl 1):103-107. doi: 10.1007/s00105-019-4369-9. German. No abstract available.

PMID:
30976855
5.

HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans.

Mockenhaupt M, Wang CW, Hung SI, Sekula P, Schmidt AH, Pan RY, Chen CB, Dunant A, Gouvello SL, Schumacher M, Valeyrie-Allanore L, Bellon T, Kardaun SH, Jan YS, Chung WH, Roujeau JC; RegiSCAR group.

Allergy. 2019 Apr 11. doi: 10.1111/all.13821. [Epub ahead of print] No abstract available.

PMID:
30972788
6.

Controversies in drug allergy: Testing for delayed reactions.

Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, Lehloenya R, Mockenhaupt M, Peter J, Pirmohamed M, Roujeau JC, Shear NH, Tanno LK, Trubiano J, Valluzzi R, Barbaud A.

J Allergy Clin Immunol. 2019 Jan;143(1):66-73. doi: 10.1016/j.jaci.2018.10.030. Epub 2018 Dec 17. Review.

PMID:
30573342
7.

EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity.

Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, Spiewak R, Torres MJ, Mortz CG.

Allergy. 2019 Jan;74(1):14-27. doi: 10.1111/all.13562. Epub 2018 Dec 5.

PMID:
30028512
8.

[Acute life-threatening drug reactions of the skin].

Mockenhaupt M.

Hautarzt. 2018 May;69(5):364-375. doi: 10.1007/s00105-018-4176-8. Review. German.

PMID:
29721625
9.

[Severe skin reactions due to new medications].

Mockenhaupt M, Paulmann M.

Hautarzt. 2018 Apr;69(4):278-289. doi: 10.1007/s00105-018-4153-2. Review. German.

PMID:
29568997
10.

Epidermal Necrolysis, Ocular Complications, and "Cold Medicines".

Roujeau JC, Dunant A, Mockenhaupt M.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):703-704. doi: 10.1016/j.jaip.2017.10.033. No abstract available.

PMID:
29525000
11.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.

12.

Is neutrophilic desquamative erythroderma a form of acute generalized exanthematous pustulosis?

Weins AB, Scharffetter-Kochanek K, Weiss T, Brockow K, Biedermann T, Psotta-Schachtner C, Mockenhaupt M, Weiss JM.

J Eur Acad Dermatol Venereol. 2018 Jun;32(6):e230-e232. doi: 10.1111/jdv.14751. Epub 2018 Jan 10. No abstract available.

PMID:
29224230
13.

Generalized Bullous Fixed Drug Eruption Following Metamizole (Re-)Exposure: A Medical Error-analytic Case Study.

Elsner P, Mockenhaupt M.

Acta Derm Venereol. 2018 Mar 13;98(3):376-377. doi: 10.2340/00015555-2840. No abstract available.

14.

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, Lertora JJL, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH.

Clin Pharmacol Ther. 2018 Mar;103(3):390-394. doi: 10.1002/cpt.890. Epub 2017 Nov 6. Review.

15.

New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.

Roujeau JC, Mockenhaupt M, Guillaume JC, Revuz J.

J Invest Dermatol. 2017 Oct;137(10):2047-2049. doi: 10.1016/j.jid.2017.07.828. Review.

16.

[Severe cutaneous drug reactions in children].

Mockenhaupt M.

Hautarzt. 2017 Oct;68(10):803-814. doi: 10.1007/s00105-017-4048-7. Review. German.

PMID:
28932875
17.

Epidemiology of cutaneous adverse drug reactions.

Mockenhaupt M.

Allergol Select. 2017 Aug 4;1(1):96-108. doi: 10.5414/ALX01508E. eCollection 2017. Review.

18.

Fever in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases: Laboratory Work-up and Antibiotic Therapy.

Paulmann M, Mockenhaupt M.

Pediatr Infect Dis J. 2017 May;36(5):513-515. doi: 10.1097/INF.0000000000001571.

PMID:
28403057
19.

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.

Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M.

JAMA Dermatol. 2017 Jun 1;153(6):514-522. doi: 10.1001/jamadermatol.2016.5668. Review.

20.

Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone.

Haddad C, Chosidow O, Valeyrie-Allanore L, Ghaleh B, Legrand T, Mockenhaupt M, Barau C, Khoudour N, Sekula P, Wolkenstein P, Hulin A.

J Invest Dermatol. 2017 May;137(5):1179-1181. doi: 10.1016/j.jid.2016.11.041. Epub 2017 Jan 17. No abstract available.

21.

Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH.

J Invest Dermatol. 2017 May;137(5):1065-1073. doi: 10.1016/j.jid.2016.11.034. Epub 2016 Dec 21.

22.

Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.

Paulmann M, Mockenhaupt M.

Curr Pharm Des. 2016;22(45):6852-6861. doi: 10.2174/1381612822666160928125152. Review.

PMID:
27779083
23.

AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production.

Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, Irvine AD, Képíró L, Mockenhaupt M, Oon HH, Pinner J, Ranki A, Seyger MMB, Soler-Palacin P, Storan ER, Tan ES, Valeyrie-Allanore L, Young HS, Trembath RC, Choon SE, Szell M, Bata-Csorgo Z, Smith CH, Di Meglio P, Barker JN, Capon F.

J Invest Dermatol. 2016 Nov;136(11):2251-2259. doi: 10.1016/j.jid.2016.06.618. Epub 2016 Jul 5.

24.

The case-crossover design via penalized regression.

Doerken S, Mockenhaupt M, Naldi L, Schumacher M, Sekula P.

BMC Med Res Methodol. 2016 Aug 22;16:103. doi: 10.1186/s12874-016-0197-0.

25.

[Unintended rechallenge : Generalized bullous fixed drug eruption in two elderly women].

Paulmann M, Mockenhaupt M.

Hautarzt. 2017 Jan;68(1):59-63. doi: 10.1007/s00105-016-3850-y. German.

PMID:
27448063
27.

Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy.

Paulmann M, Mockenhaupt M.

J Dtsch Dermatol Ges. 2015 Jul;13(7):625-45. doi: 10.1111/ddg.12747. English, German.

PMID:
26110722
28.

IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis.

Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, Chaves A, Duckworth M, Irvine AD, Mockenhaupt M, Navarini AA, Seyger MM, Soler-Palacin P, Prins C, Valeyrie-Allanore L, Vicente MA, Trembath RC, Smith CH, Barker JN, Capon F.

J Allergy Clin Immunol. 2015 Apr;135(4):1067-70.e9. doi: 10.1016/j.jaci.2014.09.043. Epub 2014 Nov 12. No abstract available.

PMID:
25458002
29.

Comments on: DRESS syndrome.

Kardaun SH, Mockenhaupt M, Roujeau JC.

J Am Acad Dermatol. 2014 Nov;71(5):1000-1000.e2. doi: 10.1016/j.jaad.2013.11.053. Epub 2014 Oct 15. No abstract available.

PMID:
25437959
31.

Management of nonimmediate hypersensitivity reactions to drugs.

Roujeau JC, Haddad C, Paulmann M, Mockenhaupt M.

Immunol Allergy Clin North Am. 2014 Aug;34(3):473-87, vii. doi: 10.1016/j.iac.2014.04.012. Review.

PMID:
25017673
32.

[Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis].

Mockenhaupt M.

Hautarzt. 2014 May;65(5):415-23. doi: 10.1007/s00105-013-2694-y. German.

PMID:
24820799
33.

[Cutaneous drug reactions. A special challenge for dermatologists].

Ständer S, Mockenhaupt M.

Hautarzt. 2014 May;65(5):396. doi: 10.1007/s00105-013-2693-z. German. No abstract available.

PMID:
24820796
34.

Assessment of the "case-chaos" design as an adjunct to the case-control design.

Doerken S, Mockenhaupt M, Schumacher M, Sekula P.

Am J Epidemiol. 2014 Mar 15;179(6):775-80. doi: 10.1093/aje/kwt310. Epub 2014 Jan 8.

PMID:
24401562
35.

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.

Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellón T, Tamouza R, Fortier C, Toubert A, Charron D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC.

Pharmacogenomics J. 2014 Jun;14(3):281-8. doi: 10.1038/tpj.2013.40. Epub 2013 Dec 10.

PMID:
24322785
36.

Travel-acquired subcutaneous Sparganum proliferum infection diagnosed by molecular methods.

Schauer F, Poppert S, Technau-Hafsi K, Mockenhaupt M, Muntau B, Häcker G, Tappe D, Jakob T.

Br J Dermatol. 2014 Mar;170(3):741-3. doi: 10.1111/bjd.12679. No abstract available.

PMID:
24124973
37.

Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH.

J Invest Dermatol. 2014 Feb;134(2):580-581. doi: 10.1038/jid.2013.349. Epub 2013 Aug 16. No abstract available.

38.

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; RegiSCAR study group.

Br J Dermatol. 2013 Nov;169(5):1071-80. doi: 10.1111/bjd.12501.

PMID:
23855313
39.

Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, Roujeau JC.

Drug Saf. 2013 Aug;36(8):681-6. doi: 10.1007/s40264-013-0070-6.

PMID:
23743691
40.

Lack of a specific humoral autoreactivity in sera from patients with early erythema exsudativum multiforme majus.

Komorowski L, Mockenhaupt M, Sekula P, Roujeau JC, Probst C, Teegen B, Li W, Stöcker W, Zillikens D.

J Invest Dermatol. 2013 Dec;133(12):2799-2802. doi: 10.1038/jid.2013.242. Epub 2013 Jun 6. No abstract available.

41.

Telaprevir-related dermatitis.

Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS.

JAMA Dermatol. 2013 Feb;149(2):152-8.

PMID:
23560295
42.

Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M.

Br J Dermatol. 2013 Apr;168(4):726-32. doi: 10.1111/bjd.12133. Epub 2013 Feb 16.

PMID:
23413807
43.

Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group.

J Invest Dermatol. 2013 May;133(5):1197-204. doi: 10.1038/jid.2012.510. Epub 2013 Feb 7.

44.

Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis.

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH.

J Invest Dermatol. 2013 Jul;133(7):1904-7. doi: 10.1038/jid.2013.44. Epub 2013 Jan 28. No abstract available.

45.

The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.

Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC.

Br J Dermatol. 2012 Sep;167(3):555-62. doi: 10.1111/j.1365-2133.2012.11074.x.

PMID:
22639874
46.

Epidemiology of cutaneous adverse drug reactions.

Mockenhaupt M.

Chem Immunol Allergy. 2012;97:1-17. doi: 10.1159/000335612. Epub 2012 May 3.

PMID:
22613850
47.

[Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].

Chronopoulos A, Pleyer U, Mockenhaupt M.

Klin Monbl Augenheilkd. 2012 May;229(5):534-9. doi: 10.1055/s-0031-1299530. Epub 2012 May 16. Review. German.

PMID:
22592345
48.

Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.

Papay J, Yuen N, Powell G, Mockenhaupt M, Bogenrieder T.

Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):289-96. doi: 10.1002/pds.2276. Epub 2011 Dec 5.

PMID:
22139991
49.

Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis.

Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC.

Clin Exp Allergy. 2012 Feb;42(2):248-54. doi: 10.1111/j.1365-2222.2011.03875.x. Epub 2011 Oct 6.

PMID:
22092454
50.

Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.

Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M.

Br J Dermatol. 2012 Mar;166(3):575-600. doi: 10.1111/j.1365-2133.2011.10705.x. Review.

PMID:
22014091

Supplemental Content

Loading ...
Support Center